Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
机构:[1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.[2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China.[3]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[4]Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.内科科室肿瘤放疗科肿瘤内科昆明医科大学附属第一医院[5]Department of Radiotherapy of the Chest and Abdomen, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.[6]Institute for Cancer Prevention and Treatment, Chongqing Sanxia Central Hospital, Chongqing, China.[7]Department of Medical Oncology, Xinqiao Hospital, Chongqing, China.[8]Department of Oncology, Southwest Hospital, Chongqing, China.[9]Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, China.[10]Department of Radiotherapy, General Hospital of Ningxia Medical University, Yinchuan, China.[11]Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.[12]GenePlus-Beijing Institute, Peking University Medical Industrial Park, Zhongguancun Life Science Park, Beijing, China.[13]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.[14]Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, USA.
National Natural Science Foundation of China (Grant No. 81972851, 81472803, ZZ. Yang) and the Foundation and Frontier Research Project of Chongqing (Grant No. cstc2015jcyjBX0084, ZZ. Yang).
第一作者机构:[1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.[2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China.[*1]No.288 Tianwen Road, Nan’an District, Chongqing, China 400000
共同第一作者:
通讯作者:
通讯机构:[1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.[2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China.[13]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.[14]Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, USA.[*1]No.288 Tianwen Road, Nan’an District, Chongqing, China 400000[*2]Department of Radiation Oncology, Unit 1422, The University of Texas MD[*3]The Ohio State University Medical Center, 488 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
推荐引用方式(GB/T 7714):
Yang Zhenzhou,Zhang Yan,Li Rongqing,et al.Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.[J].NEURO-ONCOLOGY.2021,23(6):967-978.doi:10.1093/neuonc/noaa281.
APA:
Yang Zhenzhou,Zhang Yan,Li Rongqing,Yisikandaer Abulimiti,Ren Biyong...&Carbone David P.(2021).Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial..NEURO-ONCOLOGY,23,(6)
MLA:
Yang Zhenzhou,et al."Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.".NEURO-ONCOLOGY 23..6(2021):967-978